Research programme: V 5 - Zymeworks

Drug Profile

Research programme: V 5 - Zymeworks

Alternative Names: V-5 - Zymeworks

Latest Information Update: 06 Nov 2014

Price : $50

At a glance

  • Originator Zymeworks
  • Class Antibodies; Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Lung cancer; Multiple myeloma; Renal cancer

Most Recent Events

  • 06 Nov 2014 Early research in Lung cancer, Multiple myeloma and renal cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top